Niagen Bioscience (NAGE) Company Report

Niagen Bioscience delivered strong financial performance for Q4 and full-year 2025, with net revenue of $129.4 million for the full year, representing 30% growth year-over-year, and net income of $17.4 million. The company ended 2025 with $64.8 million in cash and no debt.
For full-year 2026, the company projects net sales growth of 10%-15% year-over-year, excluding the analytical reference standards and services segment, and anticipates a slight improvement in gross margin.
Strategic initiatives include the divestiture of the ChromaDex Reference Standards business for $6 million , plans to launch Niagen Plus branded at-home injection kits in the first half of 2026 , and expansion into the beauty cosmetics market.
The company also commenced litigation against the FDA challenging its reversal on NMN marketing and announced a $10 million share repurchase program, of which $250,000 has been used to date.

2 days ago

Transcript

Niagen Bioscience Reports Strong Q4 and Full-Year 2025 Results, Provides 2026 Outlook

NAGE

Earnings

Guidance Update

Legal Proceedings

Niagen Bioscience reported Q4 2025 revenue of $33.8 million, a 16% increase year-over-year, with net income of $4.1 million or $0.05 per share. For the full year 2025, net revenue reached $129.4 million, growing 30% year-over-year, and net income was $17.4 million. The company ended 2025 with $64.8 million in cash and no debt.
For full year 2026, the company projects net sales growth between 10%-15% year-over-year, excluding revenue from the divested analytical reference standards and services segment. They anticipate a slight improvement in gross margin and expect sales pacing to be more backloaded compared to previous years.
The company completed the sale of its ChromaDex Reference Standards business for $6 million. Niagen Bioscience is expanding its Niagen Plus offerings, including launching at-home injection kits in the first half of 2026 and growing its presence in the beauty cosmetics market.
Niagen Bioscience commenced litigation against the FDA challenging its reversal on NMN as a dietary supplement, expecting the case to take about a year without significant cost impact. The company also plans to utilize the remainder of its $10 million share buyback program, having used $250,000 to date.

2 days ago

Transcript

Niagen Bioscience Reports Strong Q4 and Full-Year 2025 Results, Issues 2026 Guidance

NAGE

Earnings

Guidance Update

Product Launch

Niagen Bioscience Inc. reported Q4 2025 revenue of $33.8 million, a 16% year-over-year increase, and net income of $4.1 million. For the full year 2025, net revenue was $129.4 million, up 30% year-over-year, with net income of $17.4 million and $64.8 million in cash.
The company projects full-year 2026 net sales growth of 10%-15% year-over-year, excluding the divested ChromaDex Reference Standards business, with sales expected to be more backloaded.
Strategic initiatives include the sale of the ChromaDex Reference Standards business for $6 million , the acquisition of patents for multiple NR salt forms , and plans to launch Niagen Plus branded at-home injection kits in the first half of 2026.
Niagen Bioscience has initiated litigation against the FDA challenging its reversal on NMN marketing.
The company intends to utilize the remainder of its $10 million share repurchase program, having used $250,000 to date.

2 days ago

Transcript

Niagen Bioscience Reports Strong Full-Year 2025 Financial Results and Provides 2026 Outlook

NAGE

Earnings

Guidance Update

M&A

Niagen Bioscience reported full-year 2025 net sales of $129.4 million, a 30% year-over-year increase, with net income rising 103% to $17.4 million and basic EPS of $0.22.
The company concluded 2025 with $64.8 million in cash and cash equivalents and no outstanding borrowings, demonstrating a strong financial foundation.
For full-year 2026, Niagen Bioscience projects net sales growth of 10-15%, excluding the recently divested reference standards segment.
Strategically, the company acquired the core nicotinamide riboside (NR) patent portfolio in December 2025 and sold its analytical reference standards segment in February 2026 for approximately $6.0 million.

2 days ago

8-K

Niagen Bioscience Sells ChromaDex Reference Standards Business

NAGE

M&A

New Projects/Investments

Niagen Bioscience, Inc. (NAGE) announced the sale of its ChromaDex Reference Standards business to LGC in an all-cash transaction on February 24, 2026.
This divestiture is part of the company's strategy to streamline operations, exit non-core activities, and focus resources on NAD+ science, intellectual property, and commercial growth within the longevity industry.
The transaction closed on the same day the Asset Purchase Agreement was signed, and Niagen Bioscience will provide certain operational and administrative services to the buyer for up to six months following the closing.

Feb 26, 2026, 12:02 PM

8-K

Niagen Bioscience acquires core Nicotinamide Riboside patent portfolio

NAGE

M&A

Niagen Bioscience, Inc. acquired a comprehensive patent portfolio for nicotinamide riboside (NR) and its salt forms from Queen's University Belfast (QUB), establishing the company as the sole owner of this critical intellectual property.
The acquisition, effective December 16, 2025, includes foundational composition-of-matter patents, which are considered the strongest form of intellectual property protection.
As consideration, Niagen Bioscience will make a one-time payment of approximately $1,000,000 for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and additional one-time payments of $1,500,000 in 2035 and $2,000,000 in 2038.
This transaction terminates prior licensing and joint ownership agreements, releasing Niagen Bioscience from previous royalty and payment obligations.
Niagen Bioscience's intellectual property estate now totals more than 90 issued and pending patents worldwide, with over 50 focused solely on NR.

Dec 22, 2025, 1:32 PM

8-K

Niagen Bioscience Acquires Nicotinamide Riboside Patent Portfolio

NAGE

M&A

New Projects/Investments

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced on December 22, 2025, that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms.
The patents were acquired from Queen’s University Belfast (QUB).
This acquisition further strengthens Niagen Bioscience’s long-standing leadership and ownership position in NAD+ precursor intellectual property.

Dec 22, 2025, 1:32 PM

Press Release

Niagen Bioscience Acquires Patent Portfolio

NAGE

M&A

New Projects/Investments

Niagen Bioscience, Inc. acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen’s University Belfast (QUB).
This acquisition strengthens the company's leadership and ownership position in NAD+ precursor intellectual property.

Dec 22, 2025, 1:32 PM

Press Release

Niagen Bioscience Announces Share Repurchase Program

NAGE

Share Buyback

Niagen Bioscience, Inc. (NAGE) announced on November 6, 2025, that its Board of Directors has approved a share repurchase program.
The program authorizes the company to repurchase up to $10 million of its outstanding common stock.
The repurchases can be made over the next 24 months, with the authorization expiring on October 31, 2027.
The timing, method, pricing, and actual amounts of any repurchases will be determined by management, and there is no obligation to repurchase any shares.

Nov 6, 2025, 2:05 PM

8-K

Niagen Bioscience, Inc. Reports Strong Q3 2025 Financial Results and Reaffirms Increased Full Year Outlook

NAGE

Earnings

Guidance Update

Product Launch

Niagen Bioscience, Inc. reported net sales of $34.0 million for the third quarter of 2025, marking a 33% increase year-over-year, with net income of $4.6 million and $0.06 earnings per share.
Adjusted EBITDA increased by 120% to $6.4 million for Q3 2025.
The company reaffirmed its full-year 2025 net sales outlook of 25% to 30% year-over-year growth, an increase from the previous guidance of 22% to 27%.
Recent operational highlights include the September 2025 launch of AboutNAD®, a digital platform for NAD+ research, and the October 2025 expansion of Niagen Plus™ IV and injectable therapies to over 1,000 clinics.